Neurofilament-light chain (NfL) as a biomarker of response to higher-efficacy disease-modifying therapies

November 22, 2023

Recommend to a Colleague print

 

Includes data on NfL changes after initiation of fingolimod, ofatumumab, ocrelizumab, natalizumab, alemtuzumab and oral cladribine.

11 slides

Download the slide deck

Recommend to a Colleague

Related Posts

• Ocrelizumab use throughout the MS clinical course: highlights from ECTRIMS 2025
  October 15, 2025
• Early use and long-term safety of ofatumumab: highlights from ECTRIMS 2025
  October 7, 2025
• ECTRIMS 2025 HIGHLIGHTS – SATURDAY, SEPTEMBER 27, 2025
  September 27, 2025
• ECTRIMS 2025 HIGHLIGHTS – FRIDAY, SEPTEMBER 26, 2025
  September 26, 2025
• ECTRIMS 2025 HIGHLIGHTS – THURSDAY, SEPTEMBER 25, 2025
  September 25, 2025

Go back to home page